Adiponectin improves long-term potentiation in the 5XFAD mouse brain

Area of Science:

• Neuroscience
• Metabolic Disease Research
• Cellular Biology

Background:

• Adiponectin, an adipokine, regulates key metabolic processes and insulin sensitivity.
• Altered adipokine levels in the central nervous system are linked to Alzheimer's disease (AD) risk.
• Investigating adiponectin's role in AD pathogenesis is crucial for understanding disease mechanisms.

Purpose of the Study:

• To investigate the effects of adiponectin on hippocampal cells in an AD mouse model (5XFAD) and neuronal cells (SH-SY5Y) exposed to amyloid beta.
• To determine if adiponectin can mitigate AD-related cellular damage and synaptic dysfunction.

Main Methods:

• Treatment of 5XFAD mice hippocampi and amyloid beta-exposed SH-SY5Y cells with adiponectin.
• Assessed apoptosis signaling pathways, including cleaved caspase 3 and NF-κB.
• Measured glycogen synthase kinase 3 beta (GSK3β) activation.
• Evaluated long-term potentiation (LTP) in 5XFAD mouse hippocampi.
• Analyzed the expression of NMDA and AMPA receptors.

Main Results:

• Adiponectin treatment significantly reduced cleaved caspase 3 and NF-κB signaling, indicating inhibition of apoptosis.
• GSK3β activation was decreased following adiponectin treatment.
• Adiponectin administration enhanced hippocampal LTP in 5XFAD mice.
• Reduced expression of N-methyl-D-aspartate (NMDA) receptors and surface expression of AMPA receptors were observed.

Conclusions:

• Adiponectin effectively inhibits neuronal apoptosis and inflammatory pathways in AD models.
• The study demonstrates adiponectin's beneficial effects on hippocampal synaptic plasticity.
• Adiponectin shows promise as a therapeutic agent for Alzheimer's disease by improving synaptic function and reducing neuronal damage.